Inotuzumab ozogamicin (InO), an anti-CD22 monoclonal antibody bound to calicheamicin, has significant activity against BCP-ALL and has been used for patients with relapsed or refractory BCP-ALL as a bridge to allogeneic hematopoietic transplantation (allo-HCT). The gene discussed is CD22; the disease is acute lymphoblastic leukemia.